Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 72 entries
Sorted by: Best Match Show Resources per page
Estimating gene regulatory networks with pandaR.

Bioinformatics (Oxford, England)

Schlauch D, Paulson JN, Young A, Glass K, Quackenbush J.
PMID: 28334344
Bioinformatics. 2017 Jul 15;33(14):2232-2234. doi: 10.1093/bioinformatics/btx139.

CONTACT: [email protected] or [email protected] AND IMPLEMENTATION: PandaR is provided as a Bioconductor R Package and is available at bioconductor.org/packages/pandaR.

Cite
Schlauch D, Paulson JN, Young A, et al. Estimating gene regulatory networks with pandaR. Bioinformatics. 2017;33(14):2232-2234doi: 10.1093/bioinformatics/btx139.
Schlauch, D., Paulson, J. N., Young, A., Glass, K., & Quackenbush, J. (2017). Estimating gene regulatory networks with pandaR. Bioinformatics (Oxford, England), 33(14), 2232-2234. https://doi.org/10.1093/bioinformatics/btx139
Schlauch, Daniel, et al. "Estimating gene regulatory networks with pandaR." Bioinformatics (Oxford, England) vol. 33,14 (2017): 2232-2234. doi: https://doi.org/10.1093/bioinformatics/btx139
Schlauch D, Paulson JN, Young A, Glass K, Quackenbush J. Estimating gene regulatory networks with pandaR. Bioinformatics. 2017 Jul 15;33(14):2232-2234. doi: 10.1093/bioinformatics/btx139. PMID: 28334344; PMCID: PMC5870629.
Copy Download .nbib Format: NLM
Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Gastrointestinal cancer research : GCR

Kulke MH, Scherübl H.
PMID: 20011568
Gastrointest Cancer Res. 2009 Sep;3(5):S62-6.

Overview of the Disease ProcessIncidencePrognostic FactorsGeneral Therapy StandardsAccomplishments and Lack of Accomplishments During the YearSomatostatin AnalogsPeptide Receptor-Targeted TherapySelective Internal Radiotherapy (SIRT)CYTOTOXIC THERAPIES: TemozolomideVEGF Pathway InhibitorsmTOR InhibitorsDevelopment of BiomarkersWhat Needs to be Done (Application of the Accomplishments)Controversies and DisagreementsHistologic Classification...

Cite
Kulke MH, Scherübl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2009;3(5):S62-6
Kulke, M. H., & Scherübl, H. (2009). Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointestinal cancer research : GCR, 3(5), S62-6.
Kulke, Matthew H, and Scherübl, Hans. "Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors." Gastrointestinal cancer research : GCR vol. 3,5 (2009): S62-6.
Kulke MH, Scherübl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2009 Sep;3(5):S62-6. PMID: 20011568; PMCID: PMC2791386.
Copy Download .nbib Format: NLM
Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis.

Genome biology

Ma S, Ogino S, Parsana P, Nishihara R, Qian Z, Shen J, Mima K, Masugi Y, Cao Y, Nowak JA, Shima K, Hoshida Y, Giovannucci EL, Gala MK, Chan AT, Fuchs CS, Parmigiani G, Huttenhower C, Waldron L.
PMID: 30253799
Genome Biol. 2018 Sep 25;19(1):142. doi: 10.1186/s13059-018-1511-4.

BACKGROUND: Previous approaches to defining subtypes of colorectal carcinoma (CRC) and other cancers based on transcriptomes have assumed the existence of discrete subtypes. We analyze gene expression patterns of colorectal tumors from a large number of patients to test...

Cite
Ma S, Ogino S, Parsana P, et al. Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol. 2018;19(1):142doi: 10.1186/s13059-018-1511-4.
Ma, S., Ogino, S., Parsana, P., Nishihara, R., Qian, Z., Shen, J., Mima, K., Masugi, Y., Cao, Y., Nowak, J. A., Shima, K., Hoshida, Y., Giovannucci, E. L., Gala, M. K., Chan, A. T., Fuchs, C. S., Parmigiani, G., Huttenhower, C., & Waldron, L. (2018). Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome biology, 19(1), 142. https://doi.org/10.1186/s13059-018-1511-4
Ma, Siyuan, et al. "Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis." Genome biology vol. 19,1 (2018): 142. doi: https://doi.org/10.1186/s13059-018-1511-4
Ma S, Ogino S, Parsana P, Nishihara R, Qian Z, Shen J, Mima K, Masugi Y, Cao Y, Nowak JA, Shima K, Hoshida Y, Giovannucci EL, Gala MK, Chan AT, Fuchs CS, Parmigiani G, Huttenhower C, Waldron L. Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol. 2018 Sep 25;19(1):142. doi: 10.1186/s13059-018-1511-4. PMID: 30253799; PMCID: PMC6154428.
Copy Download .nbib Format: NLM
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U.
PMID: 32651213
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10.

BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk,...

Cite
Wang X, Su YR, Petersen PS, et al. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1800-1808doi: 10.1158/1055-9965.EPI-19-1018.
Wang, X., Su, Y. R., Petersen, P. S., Bien, S., Schmit, S. L., Drew, D. A., Albanes, D., Berndt, S. I., Brenner, H., Campbell, P. T., Casey, G., Chang-Claude, J., Gallinger, S. J., Gruber, S. B., Haile, R. W., Harrison, T. A., Hoffmeister, M., Jacobs, E. J., Jenkins, M. A., Joshi, A. D., Li, L., Lin, Y., Lindor, N. M., Marchand, L. L., Martin, V., Milne, R., Maclnnis, R., Moreno, V., Nan, H., Newcomb, P. A., Potter, J. D., Rennert, G., Rennert, H., Slattery, M. L., Thibodeau, S. N., Weinstein, S. J., Woods, M. O., Chan, A. T., White, E., Hsu, L., & Peters, U. (2020). Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1800-1808. https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang, Xiaoliang, et al. "Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1800-1808. doi: https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10. PMID: 32651213; PMCID: PMC7556991.
Copy Download .nbib Format: NLM
Association of .

Clinical cancer research : an official journal of the American Association for Cancer Research

Borowsky J, Haruki K, Lau MC, Dias Costa A, Väyrynen JP, Ugai T, Arima K, da Silva A, Felt KD, Zhao M, Gurjao C, Twombly TS, Fujiyoshi K, Väyrynen SA, Hamada T, Mima K, Bullman S, Harrison TA, Phipps AI, Peters U, Ng K, Meyerhardt JA, Song M, Giovannucci EL, Wu K, Zhang X, Freeman GJ, Huttenhower C, Garrett WS, Chan AT, Leggett BA, Whitehall VLJ, Walker N, Brown I, Bettington M, Nishihara R, Fuchs CS, Lennerz JK, Giannakis M, Nowak JA, Ogino S.
PMID: 33632927
Clin Cancer Res. 2021 May 15;27(10):2816-2826. doi: 10.1158/1078-0432.CCR-20-4009. Epub 2021 Feb 25.

PURPOSE: While evidence indicates that EXPERIMENTAL DESIGN: We measured RESULTS: The amount of CONCLUSIONS: The amount of tissue

Cite
Borowsky J, Haruki K, Lau MC, et al. Association of . Clin Cancer Res. 2021;27(10):2816-2826doi: 10.1158/1078-0432.CCR-20-4009.
Borowsky, J., Haruki, K., Lau, M. C., Dias Costa, A., Väyrynen, J. P., Ugai, T., Arima, K., da Silva, A., Felt, K. D., Zhao, M., Gurjao, C., Twombly, T. S., Fujiyoshi, K., Väyrynen, S. A., Hamada, T., Mima, K., Bullman, S., Harrison, T. A., Phipps, A. I., Peters, U., Ng, K., Meyerhardt, J. A., Song, M., Giovannucci, E. L., Wu, K., Zhang, X., Freeman, G. J., Huttenhower, C., Garrett, W. S., Chan, A. T., Leggett, B. A., Whitehall, V. L. J., Walker, N., Brown, I., Bettington, M., Nishihara, R., Fuchs, C. S., Lennerz, J. K., Giannakis, M., Nowak, J. A., & Ogino, S. (2021). Association of . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2816-2826. https://doi.org/10.1158/1078-0432.CCR-20-4009
Borowsky, Jennifer, et al. "Association of ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2816-2826. doi: https://doi.org/10.1158/1078-0432.CCR-20-4009
Borowsky J, Haruki K, Lau MC, Dias Costa A, Väyrynen JP, Ugai T, Arima K, da Silva A, Felt KD, Zhao M, Gurjao C, Twombly TS, Fujiyoshi K, Väyrynen SA, Hamada T, Mima K, Bullman S, Harrison TA, Phipps AI, Peters U, Ng K, Meyerhardt JA, Song M, Giovannucci EL, Wu K, Zhang X, Freeman GJ, Huttenhower C, Garrett WS, Chan AT, Leggett BA, Whitehall VLJ, Walker N, Brown I, Bettington M, Nishihara R, Fuchs CS, Lennerz JK, Giannakis M, Nowak JA, Ogino S. Association of . Clin Cancer Res. 2021 May 15;27(10):2816-2826. doi: 10.1158/1078-0432.CCR-20-4009. Epub 2021 Feb 25. PMID: 33632927; PMCID: PMC8127352.
Copy Download .nbib Format: NLM
Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Yuan C, Zhang X, Babic A, Morales-Oyarvide V, Zhang Y, Smith-Warner SA, Wu K, Wang M, Wolpin BM, Meyerhardt JA, Chan AT, Hu FB, Fuchs CS, Ogino S, Giovannucci EL, Ng K.
PMID: 33531435
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):757-764. doi: 10.1158/1055-9965.EPI-20-1083. Epub 2021 Feb 02.

BACKGROUND: Type 2 diabetes increases risk of developing colorectal cancer, but the association of preexisting diabetes with colorectal cancer survival remains unclear.METHODS: We analyzed survival by diabetes status at cancer diagnosis among 4,038 patients with colorectal cancer from two...

Cite
Yuan C, Zhang X, Babic A, et al. Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(4):757-764doi: 10.1158/1055-9965.EPI-20-1083.
Yuan, C., Zhang, X., Babic, A., Morales-Oyarvide, V., Zhang, Y., Smith-Warner, S. A., Wu, K., Wang, M., Wolpin, B. M., Meyerhardt, J. A., Chan, A. T., Hu, F. B., Fuchs, C. S., Ogino, S., Giovannucci, E. L., & Ng, K. (2021). Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(4), 757-764. https://doi.org/10.1158/1055-9965.EPI-20-1083
Yuan, Chen, et al. "Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,4 (2021): 757-764. doi: https://doi.org/10.1158/1055-9965.EPI-20-1083
Yuan C, Zhang X, Babic A, Morales-Oyarvide V, Zhang Y, Smith-Warner SA, Wu K, Wang M, Wolpin BM, Meyerhardt JA, Chan AT, Hu FB, Fuchs CS, Ogino S, Giovannucci EL, Ng K. Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):757-764. doi: 10.1158/1055-9965.EPI-20-1083. Epub 2021 Feb 02. PMID: 33531435; PMCID: PMC8026573.
Copy Download .nbib Format: NLM
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.

Clinical cancer research : an official journal of the American Association for Cancer Research

Singh H, Li YY, Spurr LF, Shinagare AB, Abhyankar R, Reilly E, Brais LK, Nag A, Ducar MD, Thorner AR, Shapiro GI, Keller RB, Siletti C, Clark JW, Farago AF, Lin JJ, Demetri GD, Gujrathi R, Kulke MH, MacConaill LE, Ligon AH, Sicinska E, Meyerson ML, Meyerhardt JA, Cherniack AD, Wolpin BM, Ng K, Giannakis M, Hornick JL, Cleary JM.
PMID: 33414136
Clin Cancer Res. 2021 Mar 15;27(6):1695-1705. doi: 10.1158/1078-0432.CCR-20-4073. Epub 2021 Jan 07.

PURPOSE: Receptor tyrosine kinase fusions in colorectal cancers are rare, but potentially therapeutically relevant. We describe clinical, molecular, and pathologic attributes of RTK fusion-associated colorectal cancer.EXPERIMENTAL DESIGN: We identified all cases with RTK fusions in patients with colorectal cancer...

Cite
Singh H, Li YY, Spurr LF, et al. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021;27(6):1695-1705doi: 10.1158/1078-0432.CCR-20-4073.
Singh, H., Li, Y. Y., Spurr, L. F., Shinagare, A. B., Abhyankar, R., Reilly, E., Brais, L. K., Nag, A., Ducar, M. D., Thorner, A. R., Shapiro, G. I., Keller, R. B., Siletti, C., Clark, J. W., Farago, A. F., Lin, J. J., Demetri, G. D., Gujrathi, R., Kulke, M. H., MacConaill, L. E., Ligon, A. H., Sicinska, E., Meyerson, M. L., Meyerhardt, J. A., Cherniack, A. D., Wolpin, B. M., Ng, K., Giannakis, M., Hornick, J. L., & Cleary, J. M. (2021). Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1695-1705. https://doi.org/10.1158/1078-0432.CCR-20-4073
Singh, Harshabad, et al. "Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,6 (2021): 1695-1705. doi: https://doi.org/10.1158/1078-0432.CCR-20-4073
Singh H, Li YY, Spurr LF, Shinagare AB, Abhyankar R, Reilly E, Brais LK, Nag A, Ducar MD, Thorner AR, Shapiro GI, Keller RB, Siletti C, Clark JW, Farago AF, Lin JJ, Demetri GD, Gujrathi R, Kulke MH, MacConaill LE, Ligon AH, Sicinska E, Meyerson ML, Meyerhardt JA, Cherniack AD, Wolpin BM, Ng K, Giannakis M, Hornick JL, Cleary JM. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 Mar 15;27(6):1695-1705. doi: 10.1158/1078-0432.CCR-20-4073. Epub 2021 Jan 07. PMID: 33414136.
Copy Download .nbib Format: NLM
Low glycaemic diets alter lipid metabolism to influence tumour growth.

Nature

Lien EC, Westermark AM, Zhang Y, Yuan C, Li Z, Lau AN, Sapp KM, Wolpin BM, Vander Heiden MG.
PMID: 34671163
Nature. 2021 Nov;599(7884):302-307. doi: 10.1038/s41586-021-04049-2. Epub 2021 Oct 20.

Dietary interventions can change metabolite levels in the tumour microenvironment, which might then affect cancer cell metabolism to alter tumour growth

Cite
Lien EC, Westermark AM, Zhang Y, et al. Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 2021;599(7884):302-307doi: 10.1038/s41586-021-04049-2.
Lien, E. C., Westermark, A. M., Zhang, Y., Yuan, C., Li, Z., Lau, A. N., Sapp, K. M., Wolpin, B. M., & Vander Heiden, M. G. (2021). Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature, 599(7884), 302-307. https://doi.org/10.1038/s41586-021-04049-2
Lien, Evan C, et al. "Low glycaemic diets alter lipid metabolism to influence tumour growth." Nature vol. 599,7884 (2021): 302-307. doi: https://doi.org/10.1038/s41586-021-04049-2
Lien EC, Westermark AM, Zhang Y, Yuan C, Li Z, Lau AN, Sapp KM, Wolpin BM, Vander Heiden MG. Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 2021 Nov;599(7884):302-307. doi: 10.1038/s41586-021-04049-2. Epub 2021 Oct 20. PMID: 34671163; PMCID: PMC8628459.
Copy Download .nbib Format: NLM
Unrestrained eating behavior and risk of mortality: A prospective cohort study.

Clinical nutrition (Edinburgh, Scotland)

Zhang Y, Song M, Yuan C, Chan AT, Schernhammer ES, Wolpin BM, Stampfer MJ, Meyerhardt JA, Fuchs CS, Roberts SB, Rimm EB, Willett WC, Hu FB, Giovannucci EL, Ng K.
PMID: 34653818
Clin Nutr. 2021 Nov;40(11):5419-5429. doi: 10.1016/j.clnu.2021.09.014. Epub 2021 Sep 17.

BACKGROUND & AIMS: Unrestrained eating behavior has been thought to be a proxy for diet frequency, timing, and caloric intake. We investigated the association of unrestrained eating with mortality risk in the Nurses' Health Study prospectively.METHODS: During follow-up (1994-2016),...

Cite
Zhang Y, Song M, Yuan C, et al. Unrestrained eating behavior and risk of mortality: A prospective cohort study. Clin Nutr. 2021;40(11):5419-5429doi: 10.1016/j.clnu.2021.09.014.
Zhang, Y., Song, M., Yuan, C., Chan, A. T., Schernhammer, E. S., Wolpin, B. M., Stampfer, M. J., Meyerhardt, J. A., Fuchs, C. S., Roberts, S. B., Rimm, E. B., Willett, W. C., Hu, F. B., Giovannucci, E. L., & Ng, K. (2021). Unrestrained eating behavior and risk of mortality: A prospective cohort study. Clinical nutrition (Edinburgh, Scotland), 40(11), 5419-5429. https://doi.org/10.1016/j.clnu.2021.09.014
Zhang, Yin, et al. "Unrestrained eating behavior and risk of mortality: A prospective cohort study." Clinical nutrition (Edinburgh, Scotland) vol. 40,11 (2021): 5419-5429. doi: https://doi.org/10.1016/j.clnu.2021.09.014
Zhang Y, Song M, Yuan C, Chan AT, Schernhammer ES, Wolpin BM, Stampfer MJ, Meyerhardt JA, Fuchs CS, Roberts SB, Rimm EB, Willett WC, Hu FB, Giovannucci EL, Ng K. Unrestrained eating behavior and risk of mortality: A prospective cohort study. Clin Nutr. 2021 Nov;40(11):5419-5429. doi: 10.1016/j.clnu.2021.09.014. Epub 2021 Sep 17. PMID: 34653818; PMCID: PMC8571025.
Copy Download .nbib Format: NLM
Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma.

Cancer discovery

Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, Garcia-Beccaria M, Fernandez-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenwalder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N.
PMID: 34848557
Cancer Discov. 2021 Nov 30; doi: 10.1158/2159-8290.CD-21-1077. Epub 2021 Nov 30.

Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple a-ketoglutarate-dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1-driven genetically engineered mouse models, we show that mIDH1 supports cholangiocarcinoma tumor maintenance...

Cite
Wu MJ, Shi L, Dubrot J, et al. Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-21-1077.
Wu, M. J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T. Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., Tummala, K. S., Weeresekara, V., Zhen, Y., Wu, Q., Luo, M., Shen, W., Garcia-Beccaria, M., Fernandez-Vaquero, M., Hudson, C., Ronseaux, S., Sun, Y., Saad-Berreta, R., Jenkins, R. W., Wang, T., Heikenwalder, M., Ferrone, C. R., Goyal, L., Nicolay, B., Deshpande, V., Kohli, R. M., Zheng, H., Manguso, R. T., & Bardeesy, N. (2021). Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-21-1077
Wu, Meng-Ju, et al. "Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-21-1077
Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, Garcia-Beccaria M, Fernandez-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenwalder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 2021 Nov 30; doi: 10.1158/2159-8290.CD-21-1077. Epub 2021 Nov 30. PMID: 34848557.
Copy Download .nbib Format: NLM
[No title available]

Cancer discovery

Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM.
PMID: 33926920
Cancer Discov. 2021 Oct;11(10):2488-2505. doi: 10.1158/2159-8290.CD-20-1669. Epub 2021 Apr 29.

We conducted next-generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree. In addition to frequent

Cite
Cleary JM, Raghavan S, Wu Q, et al. . Cancer Discov. 2021;11(10):2488-2505doi: 10.1158/2159-8290.CD-20-1669.
Cleary, J. M., Raghavan, S., Wu, Q., Li, Y. Y., Spurr, L. F., Gupta, H. V., Rubinson, D. A., Fetter, I. J., Hornick, J. L., Nowak, J. A., Siravegna, G., Goyal, L., Shi, L., Brais, L. K., Loftus, M., Shinagare, A. B., Abrams, T. A., Clancy, T. E., Wang, J., Patel, A. K., Brichory, F., Vaslin Chessex, A., Sullivan, R. J., Keller, R. B., Denning, S., Hill, E. R., Shapiro, G. I., Pokorska-Bocci, A., Zanna, C., Ng, K., Schrag, D., Jänne, P. A., Hahn, W. C., Cherniack, A. D., Corcoran, R. B., Meyerson, M., Daina, A., Zoete, V., Bardeesy, N., & Wolpin, B. M. (2021). . Cancer discovery, 11(10), 2488-2505. https://doi.org/10.1158/2159-8290.CD-20-1669
Cleary, James M, et al. "." Cancer discovery vol. 11,10 (2021): 2488-2505. doi: https://doi.org/10.1158/2159-8290.CD-20-1669
Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. . Cancer Discov. 2021 Oct;11(10):2488-2505. doi: 10.1158/2159-8290.CD-20-1669. Epub 2021 Apr 29. PMID: 33926920; PMCID: PMC8690974.
Copy Download .nbib Format: NLM
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, Phillips S, Carmichael JH, Sharma N, Jarnagin J, Baiev I, Shah YS, Fetter IJ, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Dubois JS, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Nipp RD, Roeland EJ, Ryan DP, Weekes CD, Wo JY, Hong TS, Bordeianou L, Ferrone CR, Qadan M, Kunitake H, Berger D, Ricciardi R, Cusack JC, Raymond VM, Talasaz A, Boland GM, Corcoran RB.
PMID: 33926918
Clin Cancer Res. 2021 Oct 15;27(20):5586-5594. doi: 10.1158/1078-0432.CCR-21-0410. Epub 2021 Apr 29.

PURPOSE: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations to facilitate ctDNA detection, requiring...

Cite
Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021;27(20):5586-5594doi: 10.1158/1078-0432.CCR-21-0410.
Parikh, A. R., Van Seventer, E. E., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K., Fish, M. G., Fosbenner, K. D., Miao, B., Phillips, S., Carmichael, J. H., Sharma, N., Jarnagin, J., Baiev, I., Shah, Y. S., Fetter, I. J., Shahzade, H. A., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Dubois, J. S., Franses, J. W., Giantonio, B. J., Goyal, L., Klempner, S. J., Nipp, R. D., Roeland, E. J., Ryan, D. P., Weekes, C. D., Wo, J. Y., Hong, T. S., Bordeianou, L., Ferrone, C. R., Qadan, M., Kunitake, H., Berger, D., Ricciardi, R., Cusack, J. C., Raymond, V. M., Talasaz, A., Boland, G. M., & Corcoran, R. B. (2021). Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20), 5586-5594. https://doi.org/10.1158/1078-0432.CCR-21-0410
Parikh, Aparna R, et al. "Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,20 (2021): 5586-5594. doi: https://doi.org/10.1158/1078-0432.CCR-21-0410
Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, Phillips S, Carmichael JH, Sharma N, Jarnagin J, Baiev I, Shah YS, Fetter IJ, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Dubois JS, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Nipp RD, Roeland EJ, Ryan DP, Weekes CD, Wo JY, Hong TS, Bordeianou L, Ferrone CR, Qadan M, Kunitake H, Berger D, Ricciardi R, Cusack JC, Raymond VM, Talasaz A, Boland GM, Corcoran RB. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 Oct 15;27(20):5586-5594. doi: 10.1158/1078-0432.CCR-21-0410. Epub 2021 Apr 29. PMID: 33926918; PMCID: PMC8530842.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 72 entries